ECSP18093777A - Derivados de pirazolopirimidina como inhibidor de quinasa - Google Patents
Derivados de pirazolopirimidina como inhibidor de quinasaInfo
- Publication number
- ECSP18093777A ECSP18093777A ECSENADI201893777A ECDI201893777A ECSP18093777A EC SP18093777 A ECSP18093777 A EC SP18093777A EC SENADI201893777 A ECSENADI201893777 A EC SENADI201893777A EC DI201893777 A ECDI201893777 A EC DI201893777A EC SP18093777 A ECSP18093777 A EC SP18093777A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyrazolopyrimidine
- derivatives
- kinase inhibitor
- present
- diseases
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de pirazolopirimidina, o a una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que están asociados con acciones inhibidoras de quinasas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160083050 | 2016-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18093777A true ECSP18093777A (es) | 2018-12-31 |
Family
ID=60785389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201893777A ECSP18093777A (es) | 2016-06-30 | 2018-12-18 | Derivados de pirazolopirimidina como inhibidor de quinasa |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10961247B2 (es) |
| EP (3) | EP3478687B1 (es) |
| JP (2) | JP2019519579A (es) |
| KR (1) | KR102329162B1 (es) |
| CN (2) | CN113135920A (es) |
| AU (1) | AU2017287762C1 (es) |
| BR (1) | BR112018074621B1 (es) |
| CA (1) | CA3025636C (es) |
| CL (1) | CL2018003511A1 (es) |
| CO (1) | CO2018013293A2 (es) |
| DO (1) | DOP2018000275A (es) |
| EC (1) | ECSP18093777A (es) |
| ES (1) | ES2977557T3 (es) |
| IL (1) | IL263306B (es) |
| MX (2) | MX393499B (es) |
| MY (1) | MY191110A (es) |
| PE (1) | PE20190811A1 (es) |
| PH (1) | PH12018502507B1 (es) |
| RU (1) | RU2714206C1 (es) |
| SA (2) | SA518400547B1 (es) |
| SG (1) | SG11201811470PA (es) |
| WO (1) | WO2018004306A1 (es) |
| ZA (1) | ZA201808431B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10392368B2 (en) | 2017-08-01 | 2019-08-27 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| CA3084962C (en) | 2017-12-28 | 2022-08-09 | Daewoong Pharmaceutical Co., Ltd. | Oxy-fluoropiperidine derivatives as kinase inhibitor |
| KR102577241B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| CN108586341B (zh) * | 2018-05-25 | 2020-05-08 | 天津商业大学 | 酰胺类化合物和其药用盐及其制备方法和药物用途 |
| CN112823005B (zh) | 2018-08-10 | 2024-08-20 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| EP3851438A4 (en) * | 2019-03-18 | 2021-11-10 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | BTK INHIBITOR, PHARMACEUTICAL SALT, POLYMORPHIC AND APPLICATION THEREOF |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
| CN115023428B (zh) * | 2020-01-21 | 2025-04-08 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| WO2021147953A1 (zh) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | 嘧啶并五元环类衍生物及其应用 |
| CN113214265B (zh) * | 2020-01-21 | 2023-07-07 | 江苏先声药业有限公司 | 嘧啶并五元环类化合物 |
| CN111620878A (zh) * | 2020-06-10 | 2020-09-04 | 中国药科大学 | 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用 |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| TW202214643A (zh) * | 2020-09-22 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | 嘧啶并吡咯類化合物 |
| CN114315838B (zh) * | 2020-09-30 | 2024-09-03 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN114907357A (zh) * | 2021-02-07 | 2022-08-16 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| JP2025525347A (ja) * | 2022-06-16 | 2025-08-05 | アンフィスタ セラピューティクス リミテッド | 標的タンパク質分解のための新規の二官能性分子 |
| CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
| JP7426544B1 (ja) * | 2022-11-28 | 2024-02-01 | 楽天グループ株式会社 | 画像処理システム、画像処理方法、及びプログラム |
| EP4707277A1 (en) * | 2023-05-04 | 2026-03-11 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic amine derivatives and pharmaceutical composition comprising same |
| WO2025121899A1 (ko) * | 2023-12-05 | 2025-06-12 | 주식회사 대웅제약 | 1-((3s,4r)-3-((2-((1-에틸-1h-피라졸-4-일)아미노)-7h-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의 제조 방법, 및 이의 중간체 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| PL373246A1 (en) | 2002-04-12 | 2005-08-22 | Pfizer Inc. | Use of ep4 receptor ligands in the treatment of il-6 involved diseases |
| KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| TWI630207B (zh) | 2005-12-13 | 2018-07-21 | 英塞特控股公司 | 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶 |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| US7705004B2 (en) * | 2007-08-17 | 2010-04-27 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| JP2011500806A (ja) | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| CN105362277A (zh) | 2008-07-16 | 2016-03-02 | 药品循环有限公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| KR20120102724A (ko) | 2009-12-01 | 2012-09-18 | 아보트 러보러터리즈 | 신규한 트리사이클릭 화합물 |
| MX342164B (es) * | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| AU2012313094B2 (en) | 2011-09-22 | 2017-02-02 | Intervet International B.V. | Pyrazole carboxamides as janus kinase inhibitors |
| AU2013204563B2 (en) * | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| EP2964647A1 (en) * | 2013-03-05 | 2016-01-13 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| AU2014287016B2 (en) | 2013-07-11 | 2018-11-01 | Acea Biosciences Inc. | Pyrimidine derivatives as kinase inhibitors |
| US9840517B2 (en) * | 2013-09-18 | 2017-12-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
| WO2015083028A1 (en) * | 2013-12-05 | 2015-06-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| CN105777756B (zh) * | 2014-07-02 | 2019-03-01 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| KR101710127B1 (ko) | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2016130920A2 (en) | 2015-02-13 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
-
2017
- 2017-06-30 CN CN202110351304.2A patent/CN113135920A/zh active Pending
- 2017-06-30 EP EP17820582.9A patent/EP3478687B1/en active Active
- 2017-06-30 PH PH1/2018/502507A patent/PH12018502507B1/en unknown
- 2017-06-30 RU RU2019102376A patent/RU2714206C1/ru active
- 2017-06-30 MY MYPI2018002167A patent/MY191110A/en unknown
- 2017-06-30 US US16/304,798 patent/US10961247B2/en active Active
- 2017-06-30 AU AU2017287762A patent/AU2017287762C1/en active Active
- 2017-06-30 CN CN201780039336.0A patent/CN109311896B/zh active Active
- 2017-06-30 MX MX2021009378A patent/MX393499B/es unknown
- 2017-06-30 PE PE2018003174A patent/PE20190811A1/es unknown
- 2017-06-30 ES ES17820582T patent/ES2977557T3/es active Active
- 2017-06-30 SG SG11201811470PA patent/SG11201811470PA/en unknown
- 2017-06-30 EP EP25207256.6A patent/EP4656249A3/en active Pending
- 2017-06-30 JP JP2018568407A patent/JP2019519579A/ja active Pending
- 2017-06-30 CA CA3025636A patent/CA3025636C/en active Active
- 2017-06-30 KR KR1020170083259A patent/KR102329162B1/ko active Active
- 2017-06-30 EP EP21190933.8A patent/EP3950691A1/en active Pending
- 2017-06-30 BR BR112018074621-5A patent/BR112018074621B1/pt active IP Right Grant
- 2017-06-30 MX MX2018016287A patent/MX388591B/es unknown
- 2017-06-30 WO PCT/KR2017/006980 patent/WO2018004306A1/en not_active Ceased
-
2018
- 2018-11-27 IL IL263306A patent/IL263306B/en active IP Right Grant
- 2018-11-28 SA SA518400547A patent/SA518400547B1/ar unknown
- 2018-11-28 SA SA521430937A patent/SA521430937B1/ar unknown
- 2018-12-07 CL CL2018003511A patent/CL2018003511A1/es unknown
- 2018-12-07 CO CONC2018/0013293A patent/CO2018013293A2/es unknown
- 2018-12-10 DO DO2018000275A patent/DOP2018000275A/es unknown
- 2018-12-13 ZA ZA2018/08431A patent/ZA201808431B/en unknown
- 2018-12-18 EC ECSENADI201893777A patent/ECSP18093777A/es unknown
-
2020
- 2020-06-04 JP JP2020097918A patent/JP7084961B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| ECSP20035588A (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| CR20150416A (es) | Inhibidores de cdc7 | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| CL2019000487A1 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |